Systemic Therapy in Men With Metastatic Castration-Resistant Prostate Cancer: American Society of Clinical Oncology and Cancer Care Ontario Clinical Practice Guideline

被引：186

作者：

Basch, Ethan ^{[1
]}

Loblaw, D. Andrew ^{[3
]}

Oliver, Thomas K. ^{[9
]}

Carducci, Michael ^{[10
]}

Chen, Ronald C. ^{[1
]}

Frame, James N. ^{[11
]}

Garrels, Kristina

Hotte, Sebastien ^{[5
]}

Kattan, Michael W. ^{[12
]}

Raghavan, Derek ^{[2
]}

Saad, Fred ^{[8
]}

Taplin, Mary-Ellen ^{[13
]}

Walker-Dilks, Cindy ^{[5
,6
]}

Williams, James ^{[14
]}

Winquist, Eric ^{[7
]}

Bennett, Charles L. ^{[15
]}

Wootton, Ted ^{[4
]}

Rumble, R. Bryan ^{[9
]}

Dusetzina, Stacie B. ^{[1
]}

Virgo, Katherine S. ^{[16
]}

机构：

[1] Univ N Carolina, Chapel Hill, NC USA

[2] Carolinas Hlth Care, Levine Canc Inst, Charlotte, NC USA

[3] Sunnybrook Hlth Sci Ctr, Odette Canc Ctr, Toronto, ON M4N 3M5, Canada

[4] Patient Representat, Toronto, ON, Canada

[5] McMaster Univ, Hamilton, ON, Canada

[6] Canc Care Ontario, Hamilton, ON, Canada

[7] London Hlth Sci Ctr, London, ON, Canada

[8] Univ Montreal, Montreal, PQ, Canada

[9] Amer Soc Clin Oncol, Alexandria, VA 22314 USA

[10] Johns Hopkins Univ, Baltimore, MD USA

[11] Charleston Area Med Ctr Hlth Syst, Charleston, WV USA

[12] Cleveland Clin, Cleveland, OH 44106 USA

[13] Dana Farber Canc Inst, Boston, MA 02115 USA

[14] Pennsylvania Prostate Canc Coalit, Camp Hill, PA USA

[15] South Carolina Coll Pharm, Columbia, SC USA

[16] Emory Univ, Atlanta, GA 30322 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 30期

关键词：

PHASE-III TRIAL; MITOXANTRONE PLUS PREDNISONE; HIGH-DOSE CALCITRIOL; DOUBLE-BLIND; ABIRATERONE ACETATE; COMPARING DOCETAXEL; INCREASED SURVIVAL; MEGESTROL-ACETATE; ZIBOTENTAN ZD4054; RANDOMIZED-TRIAL;

D O I：

10.1200/JCO.2013.54.8404

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose To provide treatment recommendations for men with metastatic castration-resistant prostate cancer (CRPC). Methods The American Society of Clinical Oncology and Cancer Care Ontario convened an expert panel to develop evidence-based recommendations informed by a systematic review of the literature. Results When added to androgen deprivation, therapies demonstrating improved survival, improved quality of life (QOL), and favorable benefit-harm balance include abiraterone acetate/prednisone, enzalutamide, and radium-223 (Ra-223; for men with predominantly bone metastases). Improved survival and QOL with moderate toxicity risk are associated with docetaxel/prednisone. For asymptomatic/minimally symptomatic men, improved survival with unclear QOL impact and low toxicity are associated with sipuleucel-T. For men who previously received docetaxel, improved survival, unclear QOL impact, and moderate to high toxicity risk are associated with cabazitaxel/prednisone. Modest QOL benefit (without survival benefit) and high toxicity risk are associated with mitoxantrone/prednisone after docetaxel. No benefit and excess toxicity are observed with bevacizumab, estramustine, and sunitinib. Recommendations Continue androgen deprivation (pharmaceutical or surgical) indefinitely. Abiraterone acetate/prednisone, enzalutamide, or Ra-223 should be offered; docetaxel/prednisone should also be offered, accompanied by discussion of toxicity risk. Sipuleucel-T may be offered to asymptomatic/minimally symptomatic men. For men who have experienced progression with docetaxel, cabazitaxel may be offered, accompanied by discussion of toxicity risk. Mitoxantrone may be offered, accompanied by discussion of limited clinical benefit and toxicity risk. Ketoconazole or antiandrogens (eg, bicalutamide, flutamide, nilutamide) may be offered, accompanied by discussion of limited known clinical benefit. Bevacizumab, estramustine, and sunitinib should not be offered. There is insufficient evidence to evaluate optimal sequences or combinations of therapies. Palliative care should be offered to all patients. (C) 2014 by American Society of Clinical Oncology

引用

页码：3436 / U133

页数：17

共 65 条

[1]

Active Biotech AB, STUD TASQ MEN MET CA

[2]

[Anonymous], 2013, CAN CANC STAT 2013

[3]

[Anonymous], Cancer Facts and Figures 2011

[4]

[Anonymous], N ENGL J MED